DIVI'S LABORATORIES LIMITED
1-72/23(P)/DIVIS/303, Divi Towers
Cyber Hills, Gachibowli, Hyderabad 500 032
Phone: 91-40-23786300 email: kishore@divislabs.com

PRESS RELEASE dated 26th May, 2018

Divi's Labs earns a Revenue of ₹. 4026 crores for FY18 on consolidated basis.

Consolidated for the year

For the year, Divi's Laboratories has earned a consolidated total revenue of ₹. 4026 crores for the financial year 2017-18 as against ₹. 4181 crores during the previous year.

PBT for the current year came to Rs. 1231 crores as against a PBT of ₹. 1395 crores for the previous year. PAT for the year is Rs. 877 crores as against a PAT of ₹. 1060 crores for the last year.

Revenue for the current year was impacted due to the Import Alert issued by US-FDA, which has since been resolved. Other Expenses include Legal & Professional Fee paid to attorneys, regulatory consultants and subject-matter specialists for remediation of the deficiencies observed and resolution of the Import Alert/warning letter issued by US-FDA.

Standalone Results

On a standalone basis, the company's earnings are as given below:

₹. in crores

Particulars	For the Quarter		For the year	
	31-03-18	31-03-17	**31-03-18**	31-03-17
Total Revenue	**1136**	1088	**3950**	4142
PBT	**396**	350	**1219**	1388
PAT	**262**	259	**870**	1053

DIVI'S LABORATORIES LTD. HYDERABAD-32 GACHIBOWLI

Forex Gain/(loss)

Particulars of forex gain/(loss) for the period are given below:

₹. in crores

Particulars	For the Quarter ended		For the year ended	
	31-03-18	31-03-17	**31-03-18**	31-03-17
Forex gain/(loss)	**23**	(29)	**25**	(39)

Dividend

The Board has recommended a dividend of ₹. 10 per share i.e., 500% for the year subject to approval of members.

Capex:

During the year, the company has capitalized Fixed Assets amounted to ₹. 586 crores. An amount of ₹. 120 crores is carried forward as Capital WIP at the end of the year for the Capital Works under execution.

Update on Regulatory inspections

The company's Unit-II at Visakhapatnam was inspected by the US-FDA during September 2017. This inspection was for full cGMP and verification of all Corrective Actions proposed against the previous Inspection observations. All previous observations were confirmed as completed and resolved. US-FDA issued Establishment Inspection Report (EIR) as a closure of the audit. Unit-II was also inspected by HPRA (Ireland) and JAZMP (Slovenia) during July-August, 2017 and the inspection concluded successfully with no critical observations.

The company's Unit-I at Choutuppal, Telangana State has also been inspected by the US-FDA during May 2018. This was a general cGMP inspection by the FDA and the inspection was concluded without any observations.